ChiCTR2400091846 版本V1.0 版本创建时间2024/11/05 09:45:19 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400091846 

最近更新日期:

Date of Last Refreshed on:

2024-11-05 09:45:09 

注册时间:

Date of Registration:

2024-11-05 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

左束支区域起搏传导束是否明确夺获对再同步化疗效和预后研究

Public title:

The effect and prognosis of LBBAP resynchronization by whether the capture of left bundle branch

注册题目简写:

English Acronym:

研究课题的正式科学名称:

左束支区域起搏传导束是否明确夺获对再同步化疗效和预后研究

Scientific title:

Study on the effect and prognosis of LBBAP resynchronization by whether the capture of left bundle branch

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

叶炀 

研究负责人:

傅国胜 

Applicant:

Yang Ye 

Study leader:

Guosheng Fu 

申请注册联系人电话:

Applicant telephone:

+86 571 8600 6811

研究负责人电话:

Study leader's
telephone:

+86 571 8600 6811

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yeyang1222@163.com

研究负责人电子邮件:

Study leader's E-mail:

fugs@zju.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市庆春东路3号

研究负责人通讯地址:

浙江省杭州市庆春东路3号

Applicant address:

3 Qingchun Road East, Hangzhou, Zhejiang, China

Study leader's address:

3 Qingchun Road East, Hangzhou, Zhejiang, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

浙江大学医学院附属邵逸夫医院

Applicant's institution:

Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University

研究负责人所在单位:

浙江大学医学院附属邵逸夫医院

Affiliation of the Leader:

Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

邵逸夫医院伦审2024研第0059号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

浙江大学医学院附属邵逸夫医院医学伦理委员会

Name of the ethic committee:

Institutional Review Boards of Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-02-01 00:00:00

伦理委员会联系人:

刘利民

Contact Name of the ethic committee:

Limin Liu

伦理委员会联系地址:

浙江省杭州市庆春东路3号

Contact Address of the ethic committee:

3 Qingchun Road East, Hangzhou, Zhejiang, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 571 8600 6811

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

浙江大学医学院附属邵逸夫医院

Primary sponsor:

Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University

研究实施负责(组长)单位地址:

浙江省杭州市庆春东路3号

Primary sponsor's address:

3 Qingchun Road East, Hangzhou, Zhejiang, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江大学医学院附属邵逸夫医院

具体地址:

浙江省杭州市庆春东路3号

Institution
hospital:

Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University

Address:

3 Qingchun Road East, Hangzhou, Zhejiang, China

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

绿城心血管病医院

具体地址:

杭州市西湖区古墩路409号

Institution
hospital:

Greentown Cardiovascular Hospital

Address:

No. 409 Gudun Road, Xihu District, Hangzhou City

国家:

中国

省(直辖市):

浙江

市(区县):

温州

Country:

China

Province:

Zhejiang

City:

Wenzhou

单位(医院):

温州医科大学附属第一医院

具体地址:

浙江省温州市鹿城区府学巷2号

Institution
hospital:

Wenzhou Medical University Affiliated First Hospital

Address:

No.2 Fuxue Lane, Lucheng District, Wenzhou City, Zhejiang Province

国家:

中国

省(直辖市):

上海

市(区县):

长宁

Country:

China

Province:

Shanghai

City:

Changning

单位(医院):

上海交通大学医学院附属同仁医院

具体地址:

上海市长宁区仙霞路1111号

Institution
hospital:

Shanghai Jiao Tong University School of Medicine Affiliated Tongren Hospital

Address:

No.1111 Xianxia Road, Changning District, Shanghai

国家:

中国

省(直辖市):

上海

市(区县):

徐汇

Country:

China

Province:

Shanghai

City:

Xuhui

单位(医院):

复旦大学附属中山医院

具体地址:

上海市徐汇区枫林路180号

Institution
hospital:

Zhongshan Hospital of Fudan University

Address:

No.180 Fenglin Road, Xuhui District, Shanghai

经费或物资来源:

自筹

Source(s) of funding:

Self sponsor

研究疾病:

完左合并心力衰竭  

Target disease:

Heart failure with LBBB

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.评估和比较 LBBAP 是否明确夺获左束支(LBBP 和 LVSP)对于不同步收缩心肌代谢、心脏重塑及预后的影响。 2.通过多影像技术比较 LBBAP 植入是否夺获传导束评估再同步化治疗疗效差别。  

Objectives of Study:

1 Evaluate and compare whether the capture the left bundle branch (LBBP or LVSP) on the impact of asynchronous contractile myocardial metabolism, cardiac remodelling and prognosis. 2 Compare the effect of LBBAP (LBBP or LVSP) by multi-imaging methods.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.≥18 周岁。 2.于浙江大学医学院附属邵逸夫医院(组长单位)等多中心就诊且诊断为左束支传导阻滞心衰(LVEF 小于 35%)需要再同步化治疗患者。 3.自愿参加本研究,并签署知情同意书。

Inclusion criteria

1.≥ 18 years old. 2. He was treated in many centres such as Shao Yifu Hospital (group leader unit) of Zhejiang University School of Medicine and was diagnosed with left-east branch block heart failure (LVEF less than 35%). Patients need to be treated with re-synchronous treatment. 3. Participate in this study voluntarily and sign an informed consent form.

排除标准:

1.诊断不明确。 2.目前有急性心梗,心外科手术,严重主动脉狭窄患者。 3.因各种原因不能参与随访。 4.活动性感染。 5.预计在 1 年之内怀孕。 6.各种代谢性疾病且可能影响本研究结果者。 7.弱势群体,包括:精神疾病者、认知损伤者、危重患者、孕妇、文盲等。 8.研究者认为不适合参加该研究的任何其他情况。

Exclusion criteria:

1. The diagnosis is unclear; 2. Patients with acute myocardial infarction, cardiac surgery, and severe aortic stenosis; 3. Unable to participate in follow-up for various reasons; 4. Active infection; 5. Pregnancy is expected within a year; 6. Various metabolic diseases that may affect the results of this study; 7.Weakable groups, including: people with mental illness, people with cognitive impairment, critically ill patients, pregnant women, illiterate, etc. 8. Any other conditions that the investigator did not consider appropriate for participation in the study.

研究实施时间:

Study execute time:

From 2023-08-04 00:00:00 To 2025-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-06-14 00:00:00 To 2025-08-01 00:00:00

干预措施:

Interventions:

组别:

左束支起搏

样本量:

64

Group:

LBBP

Sample size:

干预措施:

明确夺获传导束

干预措施代码:

Intervention:

Clearly capture the conduction bundle

Intervention code:

组别:

左室间隔起搏

样本量:

64

Group:

LVSP

Sample size:

干预措施:

无夺获传导束依据

干预措施代码:

Intervention:

No evidence of capturing the conduction beam

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

杭州 

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江大学医学院附属邵逸夫医院 

单位级别:

三甲 

Institution
hospital:

Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

疤痕分布和量和部位分析

指标类型:

主要指标

Outcome:

Scar extent, volume and location

Type:

Primary indicator

测量时间点:

术前

测量方法:

心脏磁共振增强

Measure time point of outcome:

Measure method:

contrast cardiac MRI scan

指标中文名:

左室射血分数

指标类型:

主要指标

Outcome:

LVEF

Type:

Primary indicator

测量时间点:

Baseline,1,3,6,12月,每年

测量方法:

心超

Measure time point of outcome:

Baseline, 1, 3, 6, 12months, annually

Measure method:

Echo

指标中文名:

三尖瓣环收缩期位移损伤

指标类型:

主要指标

Outcome:

TAPsEs strain

Type:

Primary indicator

测量时间点:

Baseline,1,3,6,12月,每年

测量方法:

心超

Measure time point of outcome:

Baseline, 1, 3, 6, 12months, annually

Measure method:

Echo

指标中文名:

左房大小

指标类型:

次要指标

Outcome:

LAD

Type:

Secondary indicator

测量时间点:

Baseline,1,3,6,12月,每年

测量方法:

心超

Measure time point of outcome:

Baseline, 1, 3, 6, 12months, annually

Measure method:

Echo

指标中文名:

左室大小

指标类型:

次要指标

Outcome:

LVDd

Type:

Secondary indicator

测量时间点:

Baseline,1,3,6,12月,每年

测量方法:

心超

Measure time point of outcome:

Baseline, 1, 3, 6, 12months, annually

Measure method:

Echo

指标中文名:

右室大小

指标类型:

次要指标

Outcome:

End diastolic diameter of right ventricle

Type:

Secondary indicator

测量时间点:

Baseline,1,3,6,12月,每年

测量方法:

心超

Measure time point of outcome:

Baseline, 1, 3, 6, 12months, annually

Measure method:

Echo

指标中文名:

相位直方图带宽

指标类型:

主要指标

Outcome:

PHB

Type:

Primary indicator

测量时间点:

Baseline ,1月

测量方法:

核素

Measure time point of outcome:

Baseline ,1month

Measure method:

SPECT-PET

指标中文名:

相位标准差

指标类型:

主要指标

Outcome:

PSD

Type:

Primary indicator

测量时间点:

Baseline ,1月

测量方法:

核素

Measure time point of outcome:

Baseline ,1month

Measure method:

SPECT-PET

指标中文名:

心室间机械延迟

指标类型:

主要指标

Outcome:

IVMW

Type:

Primary indicator

测量时间点:

Baseline ,1月

测量方法:

核素

Measure time point of outcome:

Baseline ,1month

Measure method:

SPECT-PET

指标中文名:

从间隔到后壁的机械延迟

指标类型:

主要指标

Outcome:

SPWMD

Type:

Primary indicator

测量时间点:

Baseline ,1月

测量方法:

核素

Measure time point of outcome:

Baseline ,1month

Measure method:

SPECT-PET

指标中文名:

QRS宽度

指标类型:

主要指标

Outcome:

QRS

Type:

Primary indicator

测量时间点:

Baseline,术中,1,3,6,12月,每年

测量方法:

心电图

Measure time point of outcome:

Baseline, intraoperative,1, 3, 6, 12months, annually

Measure method:

electrocardiogram

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 90 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

适用,利用stata软件,快速完成简单随机分组

Randomization Procedure (please state who generates the random number sequence and by what method):

Yes.by using stata software, fast completion of simple random grouping

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

受试者和观察者设盲。

Blinding:

Subjects and observers are blinded.

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

5年,ResMan临床试验公共管理平台Resman IPD(http://www.medresman.org.cn)。,

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Five years, Resman IPD(http://www.medresman.org.cn).

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

一为病例记录表(Case Record Form, CRF),采用纸质版记录患者原始资料,二为电子采集和管理系统(Electronic Data Capture, EDC),定期将CRF表录入电子表格系统进行保存、统计和分析。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

A standard data collection and management system.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-11-05 09:45:09